Business Context and Reporting Period
Company: aTyr Pharma, Inc. (ATYR)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: aTyr is a clinical-stage biotechnology company developing therapies for fibrosis and inflammation based on extracellular tRNA synthetase biology. Its lead candidate, efzofitimod, is a biologic immunomodulator in development for interstitial lung disease (ILD), specifically pulmonary sarcoidosis and systemic sclerosis-associated ILD (SSc-ILD). The company also has preclinical candidates ATYR0101 and ATYR0750.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenues | $190 | $235 |
| Net Loss | $(74,123) | $(64,022) |
| Net Loss Per Share (Basic & Diluted) | $(0.80) | $(0.86) |
| Research & Development Expenses | $60,219 | $54,372 |
| General & Administrative Expenses | $17,598 | $13,777 |
| Cash, Cash Equivalents, and Investments | $80,900 | $75,076 |
| Accumulated Deficit | $(606,164) | $(532,046) |
| Net Cash Used in Operating Activities | $(61,986) | $(69,119) |
| Net Cash Provided by Financing Activities | $66,011 | $39,864 |
Note: The company has no product sales revenue. Revenues are derived from collaboration agreements (Kyorin) and sale of drug product material.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $10.1 million (15.8%) year-over-year, driven by higher operating expenses.
- R&D Expenses: Increased by $5.8 million to $60.2 million. This was primarily due to a $3.9 million increase in efzofitimod expenses (manufacturing costs prior to data readout) and $1.5 million in preclinical development costs.
- G&A Expenses: Increased by $3.8 million to $17.6 million, attributed to pre-commercialization expenses, higher personnel costs, and professional fees.
- Financing Activity: Net cash provided by financing activities increased significantly to $66.0 million in 2025 compared to $39.9 million in 2024, driven by $66.4 million in proceeds from the Jefferies At-The-Market (ATM) offering program.
- Stock Price Volatility: The company received a Nasdaq deficiency notice in December 2025 for trading below the $1.00 minimum bid price requirement, though it has a compliance period until June 2026.
Guidance, Outlook, and Risks
Clinical Development Status
- EFZO-FIT Study (Pulmonary Sarcoidosis): In September 2025, the company announced top-line data from its Phase 3 trial. The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48 (p=0.3313). However, the study showed clinically meaningful improvements in secondary endpoints, including the King's Sarcoidosis Questionnaire (KSQ)-Lung score (p=0.0479) and Fatigue Assessment scores.
- Regulatory Path: A Type C meeting with the FDA is scheduled for mid-April 2026 to review the EFZO-FIT results and determine the path forward. The company believes the data indicates drug activity despite the primary endpoint miss.
- EFZO-CONNECT Study (SSc-ILD): Interim data announced in June 2025 showed clinically important improvement in skin scores for diffuse SSc-ILD patients. Enrollment is expected to complete in the first half of 2026.
Liquidity and Capital Resources
As of December 31, 2025, the company held approximately $80.9 million in cash, cash equivalents, and investments. Management believes this is sufficient to fund operations for at least one year. However, the company anticipates continuing to incur significant losses and will require additional capital to fund future clinical trials, regulatory submissions, and potential commercialization.
Key Risks and Contingencies
- Regulatory Uncertainty: There is no established FDA regulatory pathway for pulmonary sarcoidosis. The failure to meet the primary endpoint in the Phase 3 trial creates significant uncertainty regarding approval and may require additional costly trials.
- Legal Proceedings: Two putative securities class action complaints were filed in October 2025 alleging violations of Section 10(b) of the Exchange Act related to statements about efzofitimod. The cases were consolidated in February 2026.
- Manufacturing: The company relies on third-party CDMOs. A CDMO site relocation is underway, which could impact commercial supply planning and funding needs.
- Stock Listing: Risk of delisting from Nasdaq if the minimum bid price requirement is not met by the compliance deadline.
Investor Verification Checklist
- Primary Endpoint Failure: Verify the specific statistical analysis plan and the FDA's historical stance on secondary endpoints when a primary endpoint is missed in orphan drug indications.
- April 2026 FDA Meeting: Monitor the outcome of the scheduled Type C meeting for clarity on the regulatory path forward for efzofitimod in sarcoidosis.
- Liquidity Runway: Assess the burn rate relative to the $80.9 million cash position, considering potential costs for additional clinical trials if the FDA requires them.
- Securities Litigation: Review the status of the consolidated class action lawsuit filed in October 2025 regarding disclosures related to efzofitimod.
- Nasdaq Compliance: Track the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before June 2, 2026, to avoid delisting.
- CDMO Transition: Confirm the timeline and impact of the CDMO site relocation on drug supply for the EFZO-CONNECT study and potential future commercialization.